# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Operating Expenses The Company expects total GAAP operating expenses (selling, general & administrative expenses and resear...
OptiNose (NASDAQ:OPTN) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by...
HC Wainwright & Co. analyst Matthew Caufield reiterates OptiNose (NASDAQ:OPTN) with a Buy and maintains $5 price target.
ULBI: 26% | Ultralife shares are trading higher after the company reported better-than-expected Q1 financial results.CDTX: 41% ...
In addition, the Company announced preliminary XHANCE net product revenue of $14.9 million for the three months ended March 31,...